With one of biotech's largest private rounds in a year, ArriVent enters PhIII

Kyle LaHucik

Senior Reporter

Bing Yao’s ArriVent Biopharma has amassed a $155 million oversubscribed Series B, crowning it as one of biotech’s largest private rounds in a year-long difficult …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With one of biotech's largest private rounds in a year, ArriVent enters PhIII

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

Exclusive: Florida cancer biotech raises $100M Series A

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

PDUFAs for Tonix and Nuvation; Sanofi vaccine partnership; RAPT allergy deal

With one of biotech's largest pri­vate rounds in a year, Ar­riVent en­ters PhI­II

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

PDU­FAs for Tonix and Nu­va­tion; Sanofi vac­cine part­ner­ship; RAPT al­ler­gy deal

With one of biotech's largest private rounds in a year, ArriVent enters PhIII

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

Exclusive: Florida cancer biotech raises $100M Series A

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

PDUFAs for Tonix and Nuvation; Sanofi vaccine partnership; RAPT allergy deal